Dr Eugene Gan

Dr Eugene Gan is Senior Director, Operations at the Singapore Clinical Research Institute (SCRI) leads both an operations team that support the conduct and running of public-funded clinical trials in Singapore, as well as a coordinating office that work with various partners to strategise and execute key initiatives aimed at enhancing Singapore’s clinical trials ecosystem.

Dr Gan previously spent 10 years at the Agency for Science, Technology and Research (A*STAR) where he held several leadership roles. His most recent appointment was as the Deputy Chief Executive Officer of the Experimental Drug Development Centre (EDDC), where he led a scientific group of over 70 scientists and research associates across more than 20 projects to discover and develop novel medicines for various human diseases. He was also responsible for the EDDC Operations team, overseeing the funding strategy, project management, innovation initiatives, and general day-to-day operations of the unit.

During his tenure at A*STAR, Dr Gan was principally involved in the creation of the National Healthcare Innovation Centre, Singapore (NHIC) at the Ministry of Health, the PharmBio Cluster (now the Health and Biomedical cluster) at BMRC, the Therapeutics Development Review Grant (TDR) at BMRC, and the EBC at A*STAR. He also played a supporting role in the creation of the Research Support Centre (RSC) and several Industry Alignment Fund Pre-Positioning (IAF-PP) programmes.

Dr Gan was previously a Research Scientist at Eli Lilly & Company where he worked on several target validation and drug discovery projects. He graduated with a Bachelor of Science (with Honours) and Master of Science, both in Biochemistry from the Department of Chemistry at Indiana University in 1996 and 1999 respectively. He obtained his Doctor of Philosophy in Cancer Biology from the Department of Pharmacology and Cancer Biology at Duke University in 2007, studying the mechanisms of apoptosis in cancer.